Ingevity Corp Stock
Heavy losses for Ingevity Corp today as the stock fell by -€2.000 (-3.230%).
With 7 Buy predictions and not the single Sell prediction the community is currently very high on Ingevity Corp.
On the other hand, the target price of 59 € is below the current price of 60.0 € for Ingevity Corp, so the potential is actually -1.67%.
Pros and Cons of Ingevity Corp in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ingevity Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ingevity Corp | -3.230% | -6.977% | -8.397% | 61.638% | 20.096% | 2.564% | - |
| PTT Global Chemical -fgn- | -5.240% | -16.204% | 8.383% | 49.587% | 69.159% | -11.275% | -37.153% |
| Barito Pacific Tbk PT | 1.970% | 4.730% | 29.167% | -42.164% | -50.321% | 127.941% | 84.524% |
| Braskem Pfd ADR | 6.670% | -3.704% | -2.804% | -24.088% | -14.050% | -77.143% | -89.278% |
Comments
Ingevity (NGVT) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for NGVT provided by MarketBeat
Ingevity (NGVT) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for NGVT provided by MarketBeat
Ingevity (NGVT) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for NGVT provided by MarketBeat
News
Ingevity Q2 Earnings Call Highlights
Key Points
- Interested in Ingevity Corporation? Here are five stocks we like better.
- Strong second-quarter performance: Excluding the divested Road Markings business, sales rose 5%, while
Ingevity Q1 Earnings Call Highlights
Ingevity (NYSE:NGVT) reported higher first-quarter 2026 sales and reaffirmed its full-year outlook as management highlighted progress on portfolio simplification, strong margins in its Performance
Investor Builds $6 Million Position in Surging Chemicals Name Beating the S&P 500 by Nearly 40 Points
On February 17, 2026, EVR Research disclosed a new position in Ingevity (NYSE:NGVT), acquiring 100,000 shares worth $5.92 million.
In a U.S. Securities and Exchange Commission (SEC) filing dated
